RWA Wealth Partners LLC Raises Stake in AstraZeneca PLC $AZN

RWA Wealth Partners LLC boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 11.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 61,933 shares of the company’s stock after buying an additional 6,444 shares during the quarter. RWA Wealth Partners LLC’s holdings in AstraZeneca were worth $4,751,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in AZN. NewSquare Capital LLC increased its stake in shares of AstraZeneca by 149.3% during the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after purchasing an additional 218 shares during the last quarter. Rakuten Investment Management Inc. purchased a new stake in AstraZeneca in the third quarter worth $31,000. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of AstraZeneca by 144.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock valued at $36,000 after buying an additional 275 shares during the period. VSM Wealth Advisory LLC bought a new stake in shares of AstraZeneca in the second quarter valued at $33,000. Finally, FSA Wealth Management LLC lifted its position in shares of AstraZeneca by 376.0% during the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after buying an additional 376 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on AZN shares. Wall Street Zen lowered AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Citigroup started coverage on shares of AstraZeneca in a research note on Tuesday, January 27th. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of AstraZeneca in a research report on Friday, February 6th. Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. Finally, Barclays reissued an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Stock Performance

NASDAQ AZN opened at $206.22 on Thursday. The company’s 50 day simple moving average is $131.31 and its two-hundred day simple moving average is $100.36. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. AstraZeneca PLC has a 1 year low of $122.48 and a 1 year high of $212.71. The stock has a market capitalization of $319.82 billion, a PE ratio of 68.51, a P/E/G ratio of 1.59 and a beta of 0.34.

AstraZeneca Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be paid a dividend of $1.595 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a yield of 156.0%. AstraZeneca’s dividend payout ratio (DPR) is currently 74.83%.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.